# Nav1.8 Inhibitor

AbbVie Taps Chinese Innovation in $745 Million Bet on Next-Generation Pain Relief

Haisco Pharmaceutical has signed a global licensing deal with AbbVie for its Nav1.8 pain inhibitor, worth up to $745 million. The agreement grants AbbVie exclusive rights outside of Greater China and highlights the shift toward Chinese-developed innovative therapies in the global market.